• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

    16.24 -0.30 (-1.81%)
    Streaming Delayed Price Updated: 2:22 PM EDT, May 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Dyne Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)
    From Kirby McInerney LLP
    Via Business Wire
    News headline image
    DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    News headline image
    DYN Investors Have Opportunity to Join Dyne Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher ↗
     
    Via Benzinga
    News headline image
    Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
     
    Via Benzinga
    News headline image
    Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy ↗
    Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful... 
    Via Benzinga
    News headline image
    Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building ↗
    The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results. 
    Via Investor's Business Daily
    News headline image
    Nasdaq Dips Over 2%; US Construction Spending Falls In July ↗
     
    Via Benzinga
    News headline image
    Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates ↗
     
    Via Benzinga
    Topics Stocks
    News headline image
    Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Dyne Therapeutics Announces Key Leadership Appointments
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity? ↗
    Find out the significance of the 
    Via Talk Markets
    Topics Stocks
    News headline image
    Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday? ↗
    A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to... 
    Via Benzinga
    Topics Economy
    News headline image
    DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 ↗
    DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    News headline image
    Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details ↗
    10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
    Via Benzinga
    News headline image
    Chart Of The Day: Dyne Therapeutics - Deeply Discounted ↗
    Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United... 
    Via Talk Markets
    News headline image
    Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday ↗
     
    Via Benzinga
    News headline image
    Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React ↗
    U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September. 
    Via Benzinga
    Topics Economy
    News headline image
    The 3 Most Undervalued Biotech Stocks to Buy in June 2024 ↗
    https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
    Via InvestorPlace
    News headline image
    Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dyne Therapeutics Announces Proposed Public Offering of Common Stock
    From Dyne Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why Is Dyne Therapeutics Stock Soaring On Monday? ↗
    Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.